This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In their article, Strebel and colleagues¹ report a systematic review assessing the relative efficacy and safety of low-molecular-weight heparins used to prevent thrombosis after total hip replacement. The authors comment that for the double-blind North American Fragmin Trial (NAFT),² "This relatively low incidence of thrombosis is offset by a relatively high rate of major bleeding of 8.8% in the early preoperative group and 6.8% in the early postoperative group."¹ The authors further note that "The rates of bleeding in both of these perioperative groups are higher" than their pooled preoperative and postoperative data or the perioperative data reported by Planes et al³ and Francis et al.⁴

It is important to note that NAFT was double-blind and reported bleeding rates separately based on centrally adjudicated major bleeding; site investigator–classified major bleeding; and site investigator–classified serious bleeding. Strebel et al¹ have failed to include or comment on the site investigator–classified major and . . . [Full Text of this Article]

RELATED ARTICLE

Reporting the NAFT Major Bleeding Rates in Context: Reviewers Should Include Site Investigator–Classified Rates
Niklaus Strebel, Martin H. Prins, and Harry R. Büller
Arch Intern Med. 2003;163(3):369.
EXTRACT | FULL TEXT